CRLF2 and precursor B-cell acute lymphoblastic leukemia: We next examined the effects of ruxolitinib co-exposure upon TSLPRCART activity against CD19+ CRLF2-rearranged Ph-like B-ALL MUTZ5 cells in vitro.